MELBOURNE, Australia, 13th March 2025 – Diag-Nose.io, a leader in precision respiratory diagnostics, announces that its innovative ABEL Microsampler®, a novel nasal liquid biopsy device, has been officially registered on the Australian Register of Therapeutic Goods (ARTG). This listing enables the device to be introduced into the Australian market, expanding access to standardised nasal fluid collection for research and diagnostic applications.
The ABEL Microsampler® is a patented, first-of-its-kind device engineered to collect precise volumes of nasal fluid with unparalleled ease and accuracy. Utilising an innovative expanding probe made from an absorptive matrix, the device streamlines the collection of high-quality nasal liquid biopsies, making it ideal for omics-grade studies.
“ARTG registration allows us to offer the ABEL Microsampler® to researchers and clinicians across Australia, providing a standardised approach to nasal fluid sampling” said Eldin Rostom, CEO and Co-Founder of Diag-Nose.io. “Unlike traditional nasal swabs, which can be inconsistent, ABEL offers a controlled volume, site-specific collection method. This makes it a valuable tool for omics technologies such as proteomics and transcriptomics.”
Designed for researchers, clinicians, biobanks, and biotech companies, the ABEL Microsampler® provides an efficient and standardised method for biomarker-rich nasal fluid collection. It supports a broad range of research areas, including respiratory diseases, neurodegenerative disorders, oncology, microbiome studies, and occupational health.
GO LAB Pty Ltd, a leading Australian distributor of sample collection devices, is partnering with Diag-Nose.io to distribute the ABEL Microsampler®, its first nasal liquid biopsy device.
“In an era where downstream assays continue to push the precision and accuracy limits of human bio-analyte testing, the ABEL Microsampler® is a much welcome tool for enabling standardised, high-quality, and reproducible nasal liquid biopsy in a patient-friendly format,” said Matias Abregu, Director at GO LAB. “We are excited to add the ABEL Microsampler® to our current portfolio and support Diag-Nose.io to introduce the technology in our region.”
Diag-Nose.io and GO LAB are actively seeking early-access research partners to expand the availability of the ABEL Microsampler®.
-ENDS-
Key Facts:
- Diag-Nose.io announces its ABEL Microsampler® has been officially registered on the Australian Register of Therapeutic Goods (ARTG)
- The patented, first-of-its-kind device has been engineered to collect precise volumes of nasal fluid with unparalleled ease and accuracy.
- It supports a broad range of research areas, including respiratory diseases, neurodegenerative disorders, oncology, microbiome studies, and occupational health.
About us:
About Diag-Nose.io
Diag-Nose.io is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.
Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.
The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.
About GO LAB
GO LAB Pty Ltd is a Melbourne-based supplier of life sciences products specialising in proven at-home bio-sampling collection devices. Our growing technology portfolio of diagnostic and research products enables comprehensive multi-omic analyses of human health. In addition, our Easy Kit services provide custom kitting and logistics solutions, allowing clinical researchers and testing companies to outsource their order fulfilment needs. Our goal is to make at-home bio-sampling easily accessible, thereby increasing public participation in clinical testing and research.
Contact details:
For any questions in relation to this release or to discuss interviews, please contact:
Nicole Papoutsis
0422 418 099
